Carregando empresa
BioStem Technologies, Inc.
BSEM · Nasdaq · ·
US$ 3,88-5,0%fechamento 29 de set.
- 1M
- +9,8%
BSEM · Nasdaq · ·
US$ 3,88-5,0%fechamento 29 de set.
Do próprio 8-K da empresa.
BioStem Technologies, Inc. não tem nenhuma transcrição de teleconferência de resultados disponível.
“The recent completion of our uplisting to Nasdaq was a monumental capital markets milestone for BioStem. This achievement enhances our visibility, broadens our access to institutional capital, and reflects the significant work our team has done to strengthen the foundation of the Company,”
Citado literalmente da divulgação, e mostrado apenas quando o documento atribui a fala a uma pessoa com nome.
As divulgações saem depois do fechamento ou antes da abertura, então o movimento é o do pregão seguinte.
Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion product lines. Join BioStem’s Distribution List & Social Media: To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE , and follow us on X and LinkedIn .
A descrição da própria empresa, como aparece no rodapé da divulgação.
A citação e a descrição da empresa vêm do 8-K do item 2.02 que BioStem Technologies, Inc. protocolou em 12 de agosto de 2026; a tabela é montada a partir dos seus relatórios trimestrais. Ler a divulgação no EDGAR As cotações são ajustadas por desdobramentos e dividendos.